Biocon Limited has announced its financial results for the quarter and year ended March 31, 2026. The Board recommended a final dividend of Rs. 0.50 per share. Key highlights include the full integration of Biocon Biologics Limited (BBL) as a wholly-owned subsidiary, a change in statutory auditors to S. R. Batliboi & Associates LLP, and the appointment of several new Independent Directors to support a unified global biopharmaceutical leadership strategy.
Financial Performance for FY26
For the financial year ended March 31, 2026, Biocon reported a consolidated total income of Rs. 1,72,695 million, compared to Rs. 1,64,699 million in the previous year. The consolidated net profit for the year stood at Rs. 3,688 million. On a standalone basis, total income reached Rs. 26,661 million, with a net profit of Rs. 372 million for the same period.
Strategic Integration of Biocon Biologics
As part of its strategy to create a Unified Global Biopharmaceutical Leader, the Board approved the full integration of its subsidiary, Biocon Biologics Limited (BBL). This involves the acquisition of remaining shares from minority shareholders through a preferential issue of 87,92,317 equity shares. The Company aims to simplify its corporate structure and unlock significant operational synergies across its Biosimilars and GLP-1 portfolios.
Dividend and Governance Changes
The Board has recommended a final dividend of 10%, amounting to Rs. 0.50 per equity share of face value Rs. 5, payable on or before August 31, 2026, subject to shareholder approval. The record date for this dividend is July 3, 2026.
In a major governance update, S. R. Batliboi & Associates LLP has been recommended as the new Statutory Auditor for a 5-year term, replacing the retiring auditor B S R & Co. LLP. Additionally, the Board announced the appointment of several new independent directors, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai, effective August 1, 2026, to strengthen the company’s leadership during its transition to a unified entity.
Future Outlook and Incentive Plans
Biocon has also launched the Biocon Unity Long Term Incentive Plan 2026 to incentivize eligible employees and drive future growth. The 48th Annual General Meeting is scheduled for August 6, 2026, and will be conducted through Video Conferencing (VC/OAVM).
Source: BSE
